NCT00050167View on ClinicalTrials.gov

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

603

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

Paclitaxel

80 mg/m\^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks

DRUG

Docetaxel

75 mg/m\^2 by vein (IV) Over 1 Hour Once Every 3 Weeks

DRUG

Capecitabine

1500 mg/m\^2 by mouth Twice Daily x 2 Weeks

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00050167 - Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | Biotech Hunter | Biotech Hunter